Source: Eur Respir J 2003; 21: 1081



Rating:

Share or cite this content

Citations should be made in the following way:
Biswas A.K., Fruedenthal W.C.. Levalbuterol toxicity: no reason to be jittery. Eur Respir J 2003; 21: 1081

Member's Comments

No comment yet.

Related content which might interest you: Cleaning agents: how they look like and how might they cause respiratory harm? Source: International Congress 2018 – Cleaning agent exposures: are they really harmful to lung health? Year: 2018 Marijuana and the lung: hysteria or cause for concern? Source: Breathe, 14 (3) 196; 10.1183/20734735.020418 Year: 2018 Paracetamol use and the risk of wheeze: causation or bias? Source: Annual Congress 2009 - Early life and childhood asthma - new results from old birth cohorts Year: 2009 What is this thing called somnolence? Source: Eur Respir J 2011; 37: 7-8 Year: 2011 Theophylline again? Reasons for believing Source: Eur Respir J 2009; 34: 5-6 Year: 2009 The side-effects of TB therapy: myth and reality Source: Annual Congress 2005 - PG10 - The management of tuberculosis: tradition and novelties Year: 2005 Introducing a new formulation of pirfenidone to reduce tablet burden for the IPF patient: Is it tolerable? Is it easy to take? What do our patients think? Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 LATE-BREAKING ABSTRACT: Tackling the burden of chronic cough: A dose escalation study of AF-219 Source: International Congress 2016 – Late-breaking topics in airways disease Year: 2016 Breathlessness: respiratory, cardiac, or something else? Source: International Congress 2015 – Primary Care Programme Year: 2015 Residual excessive sleepiness in long term CPAP-treated patients: a leak problem? Source: International Congress 2018 – New diagnostic tools for sleep and breathing and healthcare provision options Year: 2018 Immunotherapy: when, who and which drug? Source: International Congress 2018 – New drugs, strategies and research designs for advanced non-small cell lung cancer Year: 2018 Opioids in COPD: a cause of death or a marker of illness severity? Source: Eur Respir J 2016; 48: 1520-1521 Year: 2016 Opioids in COPD: a cause of death or a marker of illness severity? Source: Eur Respir J 2016; 48: 1521-1522 Year: 2016 Fooling the brain to alleviate dyspnoea Source: Eur Respir J, 50 (2) 1701383; 10.1183/13993003.01383-2017 Year: 2017 New inhaler devices: the good, the bad, and the ugly Source: International Congress 2015 – Inhaled drugs: within and beyond the lungs Year: 2015 Deprescribing of inhaled corticosteroids in patients with COPD with mild or moderate airflow limitation: what do patients think? Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD Year: 2019 Difficult-to-wean patients: can we avoid the problem? Source: ERS Skills Course 2016 Year: 2016 A case of unexplained dyspnoea: when lung function testing matters! Source: Breathe, 14 (4) 325; 10.1183/20734735.025018 Year: 2018 Treating non-adherence: the rest is pointless if the drugs stay in the cupboard! Source: International Congress 2017 – Cystic fibrosis in children and adults: treatment dilemmas Year: 2017